WCN26-2178 ADMA AS AN ENDOTHELIAL BIOMARKER: DOES IT PREDICT VASCULAR ACCESS DYSFUNCTION IN HEMODIALYSIS PATIENTS?

Read full text Summarise with VIRAT
Authors: Darryl Virgiawan Tanod, Maruhum Bonar Hasiholan Marbun, Stella Palar, Hamza Shatri
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Vascular access (VA) is a critical component of chronic hemodialysis (HD). Failure of either an arteriovenous fistula (AVF) or a tunneled central venous catheter (tCVC) reduces dialysis adequacy, increases morbidity and mortality, and adds substantial healthcare costs. A central mechanism of access failure is endothelial injury leading to venous stenosis and thrombosis. Asymmetric Dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS), the enzyme responsible for producing nitric oxide (NO) a key molecule that maintains endothelial function and vasodilation.

Fields of Study & Subjects

Central Venous Catheters and Hemodialysis Nitric Oxide and Endothelin Effects Cardiovascular Health and Disease Prevention

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105184–105184
Publication date
25 March 2026
Language
EN